Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition-Reference-Cited by-同舟云学术

Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition

Published:2019-04-26 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Zhang Lei,Chen Ying,Li Fangxuan,Bao Lewen,Liu Wenxin

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference47 articles.

1. Epidemiology and treatment patterns of epithelial ovarian cancer;Jessmon;Expert Rev Anticancer Ther,2017

2. Treatment of recurrent ovarian cancer;Pignata;Ann Oncol,2017

3. Antiangiogenic agents in gynecological cancer: state of art and perspectives of clinical research;Gadducci;Crit Rev Oncol Hematol,2015

4. Issues and promises of bevacizumab in prostate cancer treatment;Cereda;Expert Opin Biol Ther,2018

5. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer;Schmidt;Semin Immunopathol,2018

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-cell RNA sequencing reveals the change in cytotoxic NK/T cells, epithelial cells and myeloid cells of the tumor microenvironment of high-grade serous ovarian carcinoma;Discover Oncology;2024-09-09

2. The Immune Response of Cancer Cells in Breast and Gynecologic Neoplasms;International Journal of Molecular Sciences;2024-06-05

3. Skin metastasis from ovarian cancer with somatic BRCA1 mutation: A case report and literature review;Oncology Letters;2024-06-03

4. Direct antitumor activity of bevacizumab: an overlooked mechanism?;Frontiers in Pharmacology;2024-04-23

5. Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer;Biochemical Pharmacology;2023-09